Raul Cordoba: CART cell therapy is a feasible treatment option for older patients with lymphoma
Raul Cordoba shared a paper by Rebeca Bailén et al. on X:
“CART cell therapy is a feasible treatment option for older patients with lymphoma. Let’s work against ageism.
Hematology Anti-CD19 CART Cell Therapy in Elderly Patients: Multicentric Real-World Experience from GETH-TC (Spanish Group of Stem Cell Transplantation and Cell Therapy) and GELTAMO (Spanish Group of Lymphoma and Autologous Stem Cell Transplantation).”
Authors: Rebeca Bailén, Gloria Iacoboni, Javier Delgado, Lucía López-Corral, Rafael Hernani-Morales, Valentín Ortiz-Maldonado, Manuel Guerreiro, Ana Carolina Caballero, María Luisa Guerra-Domínguez, Jose Maria Sánchez-Pina, Marta Peña, Anna Torrent, Antonio Pérez-Martínez, Mariana Bastos-Oreiro, Juan Luis Reguera-Ortega, Alejandro Martín, Juan Carlos Hernandez-Boluda, Nuria Martínez-Cibrián, Jaime Sanz, Javier Briones, Hugo Luzardo Henriquez, María Calbacho, Alberto Mussetti, Juan Manuel Sancho, Pere Barba, Mi Kwon
Source: Raul Cordoba/X
Raúl Córdoba Mascuñano, MD, PhD is a specialist in hematology and hemotherapy. He is the Chair of Community Stakeholder Committee at European Hematology Association (EHA) and Coordinator of the Lymphoma Unit and Associate Chief of Hematology Department at Jiménez Díaz Foundation. He is the principal investigator for numerous clinical trials for non-Hodgkin lymphoma, Hodgkin lymphoma, chronic lymphocytic leukemia and other chronic lymphoproliferative syndromes. He is a member of the ethical review board at his current workplace.
